胰岛素对HT22细胞中IR和GLP1-R表达的作用
Melek Tunc-Ata1, Zeynep Mine Altunay2, Aysel Alphan3
1Department of Physiology, Faculty of Medicine, Pamukkale University, Denizli, Turkey. melekt@pau.edu.tr.
Medical oncology (Northwood, London, England)
|September 15, 2023
概括
胰岛素会影响大脑细胞胰岛素受体 (IR) 和葡萄糖样1受体 (GLP1-R) 随时间和剂量的表达. 这项研究揭示了胰岛素对海马细胞中这些关键受体的短期和长期影响.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 胰岛素作为大脑中的生长因子,通过胰岛素受体 (IR) 激活PI3K-AKT通路.
- 类似葡萄糖类1 (GLP-1) 提供神经保护,支持神经发生,并增强胰岛素信号传递.
- 了解胰岛素对大脑受体的影响对于神经退行性疾病研究至关重要.
研究的目的:
- 研究不同剂量和时间间隔的胰岛素如何影响胰岛素受体 (IR),胰岛素受体A (IRA),胰岛素受体B (IRB) 和葡萄糖样1受体 (GLP1-R) 的mRNA和蛋白质表达.
- 分析胰岛素对小鼠海马细胞系 (HT22) 中关键信号分子的剂量和时间依赖的影响.
主要方法:
- 利用在特定密度条件下培养的老鼠海马HT22细胞.
- 用5,10和40nM度的胰岛素治疗细胞,在0.5,2,8,16和24小时收集样本.
- 使用RT-PCR和西方斑点分析量化目标受体的mRNA和蛋白质水平.
主要成果:
- 胰岛素对胰岛素受体 (IR) 和类似葡萄糖1受体 (GLP1-R) 的表达产生了短期和长期的影响.
- 观察到的效应取决于所服用的胰岛素剂量和暴露的持续时间.
- 观察到胰岛素对IR异型 (IRA,IRB) 和GLP1-R的不同调节.
结论:
- 胰岛素显著影响海马细胞中的IR和GLP1-R的表达,这种表达取决于剂量和时间.
- 这些发现提供了关于大脑中胰岛素信号传递的复杂调节的见解.
- 这些结果可能会为未来的治疗策略提供信息,以针对神经疾病的IR异型和GLP1-R.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Glucagon-like Receptor Agonists
357
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
357
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Oral Hypoglycemic Agents: Glinides
183
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
183


